Abbott to launch RS Virus antibody.

Published: 2006-01-17 06:58:00

Updated: 2006-01-17 06:58:00

Abbott Korea announced to launch Synagis (palivizumab), a monoclonal antibody for the prevention of serious respiratory infection due to respiratory syncytial virus (RSV) infection in pediatric patients at high risk of RSV from Jan. 11 this year.

About 90% of hospitalized babies on a capillary...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK